GFM
CCCC icon

GF Fund Management’s C4 Therapeutics CCCC Stock Holding History

GF Fund Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.4K Sell
2,012
-153
-7% -$523 ﹤0.01% 541
2026
Q1 		$5.69K Buy
2,165
+262
+14% +$617 ﹤0.01% 601
2025
Q4 		$3.63K Buy
1,903
+440
+30% +$1.04K ﹤0.01% 631
2025
Q3 		$3.25K Sell
1,463
-288
-16% -$691 ﹤0.01% 615
2025
Q2 		$2.5K Hold
1,751
– – ﹤0.01% 646
2025
Q1 		$2.8K Buy
1,751
+269
+18% +$802 ﹤0.01% 644
2024
Q4 		$5.33K Buy
+1,482
New +$7.37K ﹤0.01% 609

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

GF Fund Management's CCCC Position: Q2 2026 in Review

GF Fund Management reduced its C4 Therapeutics (CCCC) stake by 7.1% in Q2 2026, selling an estimated $523 and leaving 2,012 shares worth $9.4K. The position accounts for ﹤0.01% of the portfolio, ranked #541.

GF Fund Management first reported a position in CCCC in Q4 2024 and has held it in 7 quarters since. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • GF Fund Management held 2,012 shares of C4 Therapeutics worth $9.4K as of Q2 2026.
  • GF Fund Management sold 153 C4 Therapeutics shares in Q2 2026, an estimated $523.
  • C4 Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #541 holding.
  • GF Fund Management first reported a position in C4 Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.